GlobeNewswire Inc | Jan 5, 2022 07:00AM EST

January 05, 2022

NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference.

Renalytixs management is scheduled to present on Wednesday, January 12, 2022, at 2:15 p.m. EST. Interested parties may access a live and archived webcast of the presentation on the Investors section of the company website at investors.renalytix.com.

About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Companys lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc www.renalytix.comJames McCullough, CEO Via Walbrook PR Stifel (Nominated Adviser, Joint Tel: 020 7710 7600Broker)Alex Price / Nicholas Moore Investec Bank plc (Joint Broker) Tel: 020 7597 4000Gary Clarence / Daniel Adams Walbrook PRLimited Tel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391 303 CapComm Partners Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com